QCG
WX

Quadrant Capital Group’s WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS WX Stock Holding History

Quadrant Capital Group’s Portfolio WX Stock Details WX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-162
Closed -$5K – 1810
2015
Q3 		$5K Buy
162
+35
+28% +$1.48K ﹤0.01% 828
2015
Q2 		$4K Buy
+127
New +$5.36K ﹤0.01% 887

Other funds holding WX

Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
CCS
Crosspoint Capital Strategies Orinda, California $50.4M AUM 15.37% 1-Year Est. Return

Quadrant Capital Group's WX Position: Q4 2015 in Review

Quadrant Capital Group sold out of WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS (WX) in Q4 2015, closing a stake of 162 shares — an estimated $5K sold.

Quadrant Capital Group first reported a position in WX in Q2 2015 and held it in 2 quarters. The position peaked at $5K in Q3 2015. 2 funds tracked by Wall St. Rank hold WX as of Q4 2015.

  • Quadrant Capital Group reported no remaining WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position as of Q4 2015 after selling out during the quarter.
  • Quadrant Capital Group sold 162 WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS shares in Q4 2015, an estimated $5K.
  • Quadrant Capital Group first reported a position in WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS in Q2 2015 and held it in 2 quarters.
  • Quadrant Capital Group's WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position peaked at $5K in Q3 2015.
  • 2 funds tracked by Wall St. Rank held WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS as of Q4 2015.

Based on Quadrant Capital Group's 13F filing for Q4 2015, filed 28 Jan 2016.